The short answer
Nicotinamide riboside is 255.25 Da and nicotinamide mononucleotide is 334.22 Da. Both are precursors cells convert into NAD+ through the salvage pathway, and both are small enough to be taken up in ways NAD+ itself is not, which is why almost all human trial data uses them.
Key facts
- NR
- 255.25 Da, C11H15N2O5+, CID 439924
- NMN
- 334.22 Da, C11H15N2O8P, CID 14180
- NAD+
- 663.4 Da, over twice NR
- Route
- Salvage pathway
- NR to NMN
- Phosphorylation by NRK enzymes
- NMN to NAD+
- Adenylylation by NMNAT
The salvage pathway
Cells do not usually build NAD+ from scratch. They recycle it from nicotinamide-containing fragments, the products of NAD+ consumption by sirtuins, PARPs and CD38. Supplying NR or NMN feeds that existing recycling route rather than establishing a new one, which is why both work as precursors at all.
How each enters
NR is phosphorylated by nicotinamide riboside kinases to make NMN. NMN is then adenylylated by NMNAT enzymes to make NAD+. So NR is one step further back than NMN, and NMN is the immediate precursor. NR crosses into the cell as the smaller uncharged-at-that-position molecule; NMN's route has been the subject of more debate, since it carries a phosphate.
Research material referenced
NAD+ 500mg, third-party HPLC tested
Why size and charge decide this
NR at 255.25 Da is under 40% of NAD+'s mass and lacks the pyrophosphate bridge entirely. NMN at 334.22 Da carries one phosphate rather than two. Both are substantially less encumbered than the finished coenzyme, and the pattern is consistent: the further back down the pathway, the easier the molecule is to deliver.
What the trials used
NADPARK, published in Cell Metabolism in 2022, was a randomised phase I trial of nicotinamide riboside in Parkinson's disease. Orr and colleagues ran a randomised placebo-controlled trial of NR in older adults, published in GeroScience in 2024. Yoshino and colleagues published NMN work in Science in 2021. The precursor choice is uniform across the serious literature.
Which is better
Not settled, and the question is more contested than either side's marketing suggests. NR has more published randomised trial data; NMN has the higher-profile single result in Yoshino's Science paper. Both raise measured NAD+-related markers in at least some tissues. Neither has demonstrated the downstream clinical outcomes the field is interested in.
Quick reference
| MW | Phosphates | Steps to NAD+ | |
|---|---|---|---|
| Nicotinamide riboside | 255.25 Da | None | Two |
| Nicotinamide mononucleotide | 334.22 Da | One | One |
| NAD+ | 663.4 Da | Two | - |
Frequently asked questions
What is the difference between NR and NMN?
NR is one step further back in the pathway. Cells phosphorylate NR to NMN, then convert NMN to NAD+.
Which has more trial data?
NR, including NADPARK in Cell Metabolism 2022 and a placebo-controlled study in older adults in GeroScience 2024. NMN's highest-profile result is Yoshino 2021 in Science.
Why not just supply NAD+?
It is over twice NR's mass, carries two negative charges, and does not cross membranes. Precursors do.
Continue researching
Related guides and reference material.
Primary sources & clinical trials
Published papers, trial registrations, regulator pages and company announcements. Links open the original.
- PubMedBrakedal B et al., The NADPARK study: a randomized phase I trial of nicotinamide riboside. Cell Metab 2022 (PMID 35235774)pubmed.ncbi.nlm.nih.gov
- PubMedYoshino M et al., Nicotinamide mononucleotide increases muscle insulin sensitivity. Science 2021 (PMID 33888596)pubmed.ncbi.nlm.nih.gov
- PubChemPubChem · Nicotinamide riboside (CID 439924)pubchem.ncbi.nlm.nih.gov
- PubChemPubChem · Nicotinamide mononucleotide (CID 14180)pubchem.ncbi.nlm.nih.gov
Written and published by UK Peptides, the trading name of AURYXRESEARCH LTD (company 17388727, registered in England and Wales).
Questions or a correction? Email hello@ukpeptides.org or call +44 7426 987848.
More NAD+ articles
- NAD+ and Ageing: What Is Actually EstablishedTissue NAD+ falls with age, and Covarrubias 2020 identified a mechanism - senescent cells raising CD38. Whether restoring it helps is a separate question.
- What the Human Trials Actually FoundNADPARK, Orr 2024, Yoshino's Science paper and Yi 2023. Real randomised data - and uniformly on precursors rather than NAD+ itself.
- NAD+, NMN and NR: Three Points on One PathwayNot three competing compounds but three positions in a single conversion sequence. Which has the trial data, and which is hardest to deliver.
- NAD+ Storage: Different Chemistry, Different RisksNot a peptide, so peptide degradation logic does not apply. The bonds at risk are glycosidic and pyrophosphate, and both hydrolyse readily.
- NAD+ Regulatory StatusNo marketing authorisation as a medicine anywhere. Why a precursor's food supplement status proves nothing, and why ageing language is the real hazard here.